Biotechnology

Filter

Current filters:

None

Popular Filters

1970 to 1994 of 2442 results

QPS buys majority of Austria's largest independent CRO

29-08-2012

In a second European acquisition, USA-based QPS, a full-service GLP/GCP-compliant contract research organization,…

BiotechnologyJSW Life SciencesMarkets & MarketingPharmaceuticalQPS HoldingsResearch

Gilead's Stribild, formerly "Quad," gets FDA nod

29-08-2012

The US Food and Drug Administration has approved US biotech firm Gilead Sciences' (Nasdaq: GILD) Stribild…

Anti-viralsBiotechnologyGilead SciencesNorth AmericaQuadRegulationStribild

Pharmaceutical sales rep access reducing most among oncologists in USA

28-08-2012

As more pharmaceutical companies prepare to bring new oncology drugs to market, their sales representatives…

BiotechnologyManagementMarkets & MarketingNorth AmericaOncologyPharmaceutical

FDA calls on Genzyme to re-file Lemtrada sBLA

28-08-2012

French drug major Sanofi (Euronext: SAN) revealed yesterday that its US biotech subsidiary has received…

BayerBiotechnologyGenzymeLemtradaNeurologicalNorth AmericaPharmaceuticalRegulationSanofi

Synergy Pharma gains rights to shingles drug from Bristol-Myers

28-08-2012

US biopharma firm Synergy Pharmaceuticals (Nasdaq: SGYP) has signed an asset purchase agreement with…

Anti-viralsBiotechnologyBristol-Myers SquibbFV-100Mergers & AcquisitionsSynergy Pharmaceuticals

Cancer treatments top breakthrough medicines list, Australian study finds

27-08-2012

A cure for cancer is still to be found but more new treatments have been approved for Australians with…

Asia-PacificBiotechnologyHealthcareMarkets & MarketingPharmaceuticalResearch

Bristol-Myers drops hep C pill on patient safety issues

24-08-2012

US drug major Bristol-Myers Squibb (NYSE: BMY) has discontinued development of BMS-986094 (formerly known…

Anti-viralsBiotechnologyBMS-986094Bristol-Myers SquibbPharmaceuticalRegulationResearch

Pharming first-half 2012 net loss nearly doubles

24-08-2012

Netherlands-based biotech company Pharming (NYSE Euronext: PHARM), which recently revealed that it is…

BiotechnologyFinancialPharming

Gilead abandons development of PAH drug cicletanine

23-08-2012

US biotech firm Gilead Sciences (Nasdaq: GILD), the world leader in HIV/AIDS drugs, has discontinued…

BiotechnologycicletanineGilead SciencesRare diseasesResearchRespiratory and Pulmonary

Australia's BTWG opens discussion on cuts to R&D Tax Incentive

23-08-2012

The Australian Business Tax Working Group (BTWG) has issued a discussion paper, which includes amongst…

Asia-PacificBiotechnologyFinancialPharmaceuticalResearch

EMA accepts Dynavax' filing for hep B drug Heplisav

23-08-2012

US biotech firm Dynavax Technologies (Nasdaq: DVAX) revealed yesterday that the European Medicines Agency…

Anti-viralsBiotechnologyDynavax TechnologiesEuropeHeplisavRegulationVaccines

Study confirms economic viability of orphan drugs positioned for unmet medical needs

22-08-2012

Orphan drugs achieve blockbuster status in 2011 and generate over $50 billion in revenue, according to…

BiotechnologyFinancialMarkets & MarketingPharmaceutical

NICE says Roche's Avastin in breast cancer does not provide enough benefit to justify its cost

21-08-2012

The latest and final guidance from the UK's drug watchdog the National Institute for Health and Clinical…

AvastinBiotechnologyEuropeOncologyPharmaceuticalPricingRegulationRoche

Pharmacyclics gets second $50 million milestone from Janssen

21-08-2012

California, USA-based Pharmacyclics (Nasdaq: PCYC) announced yesterday that the SPARK (MCL2001) clinical…

BiotechnologyFinancialibrutinibJanssenJohnson & JohnsonOncologyPharmaceuticalPharmacyclicsResearch

Dainippon Sumitomo to set up DSP Cancer Institute

21-08-2012

Japanese drug major Dainippon Sumitomo Pharma (TYO: 4506) says it plans to establish a new organization…

BiotechnologyDainippon Sumitomo PharmaManagementOncologyPharmaceuticalResearch

New entrants from Roche and Novartis will drive breast cancer market

20-08-2012

Through 2021, the uptake of three new market entrants, Roche (ROG: SIX)/Genentech's Perjeta (pertuzumab)…

AfinitorBiotechnologyMarkets & MarketingNovartisOncologyPerjetaPharmaceuticalRoche

AHF calls for Gilead's Quad HIV pill to be put on "prior authorization" status

19-08-2012

In what may be an unprecedented move on drug pricing and access, advocates from the AIDS Healthcare Foundation…

Anti-viralsBiotechnologyGilead SciencesNorth AmericaPharmaceuticalPricingQuadRegulation

Idenix plunges as FDA puts clinical hold on hepatitis C drug candidate

17-08-2012

US biotech firm Idenix Pharmaceuticals (Nasdaq: IDIX) saw its shares tank 29% to $5.91 in morning trading…

Anti-viralsBiotechnologyIdenix PharmaceuticalsIDX184North AmericaPharmaceuticalRegulationResearch

TG Thera in up to $250 million deal with Rhizen

17-08-2012

US development stage company TG Therapeutics (GTX:OTC B) has entered into an exclusive global agreement…

BiotechnologyImmunologicalsLicensingOncologyRhizen PharmaceuticalsTG TherapeuticsTGR-1202

1970 to 1994 of 2442 results

Back to top